[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-platelets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-platelets":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100443035","platelets-activation-in-brain-neoplasms-100443035",false,"NCT05049148","Platelets Activation in Brain Neoplasms","Observation of Platelets in Primary and Secondary Tumors of the Central Nervous System and Association With Survival: a Prospective Cohort Study","Platon","Inclusion Criteria:\n\n* Patient to undergo excision or biopsy of a brain or medullary tumor\n* Patient over 18 years old\n* Express consent to participate in the study\n* Affiliate member of the Social Security system\n\nExclusion Criteria:\n\n* Tumor sample volume not allowing the performance of additional analyzes\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Platelets are primarily known for their central role in primary hemostasis. However, they are increasingly recognized for their participation in various non-hemostatic processes, such as cancer progression and clinical expression. Experimental and clinical data indicate that the involvement of platelets in the pathophysiology of cancer goes far beyond the realm of cancer-associated thrombosis.\n\nSeveral experimental studies have shown that platelets can promote the metastatic process by various mechanisms. However, while it has been shown in vitro that direct contact with platelets initiates tumor cells for metastasis, it remains unclear whether such contacts occur in solid tumors. In addition to their ability to promote metastasis, platelets have been shown to stimulate angiogenesis and play a crucial role in lymphangiogenesis.\n\nConsidering that blood vessels, lymphatics and immune cells are major components of the tumor ecosystem, our hypothesis is that platelets contribute to the development and \u002F or regulation of the tumor microenvironment. This is because platelets stabilize tumor blood vessels by permanently repairing vascular damage caused by immune cells infiltrating tumors. Targeting platelets destabilizes tumor vessels, causing intra-tumor hemorrhage, which allows intra-tumor accumulation of intravenously administered anti-tumor drugs such as paclitaxel and improves their efficacy.\n\nStudies have also reported the role of platelets in several pathogenic mechanisms of cancer: thrombocytosis is a paraneoplastic syndrome which suggests a poor prognosis in patients with solid tumors; a negative correlation between the platelet count and the response to chemotherapy has been reported in several types of cancer; histological analyzes of esophageal cancer suggested a possible association between the presence of platelets in the tumor stroma and the level of tumor lymphangiogenesis and lymphovascular invasion; finally, a recent study reported the expression of one of the main targets of immunotherapies, PD-L1, on the platelets of patients suffering from different types of solid cancers.\n\nAll of these data support our hypothesis that platelets are components and \u002F or regulators of the tumor microenvironment and therefore potential targets for the improvement of anti-tumor therapies. In this context, the objectives of our project are to determine whether platelets are components of the microenvironment of tumors of the central nervous system, and to study the possible correlations between the intratumoral presence of platelets and the evolution of patients with central nervous system tumors",[27,28,29,30],"Glioma","Blood Platelets","Inflammation","Brain Neoplasms",[32],"Platelets activation","RECRUITING","2025-12-30",{"date":36,"type":37},"2026-01-05","ACTUAL",{"date":39,"type":37},"2022-10-27",{"date":41,"type":21},"2029-10",{"name":43,"class":44},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":72,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":45},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":20,"type":21},[57],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[60,61,62,63,64,28,65,66,67,68,69,70,71],"ACS - Acute Coronary Syndrome","Ticagrelor","Microbiota","Platelet Aggregation","Myocardial Infarction (MI)","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[73,74,75,76,77,78,79,80,81,82],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","NOT_YET_RECRUITING","2025-09-25",{"date":86,"type":37},"2025-10-02",{"date":88,"type":21},"2026-01-01",{"date":90,"type":21},"2027-06-30",{"name":92,"class":93},"Collegium Medicum w Bydgoszczy","OTHER",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":45},"100578262","group-o-whole-blood--storage-lesion-impact-and-inflammation-100578262","NCT06809010","grouP O wholE blooD : storagE leSion impacT And infLammation","grouP O wholE blooD (LTO-WB): storagE leSion impacT And infLammation","PEDESTAL EFS","Inclusion Criteria:\n\nSelf-referred donors eligible for blood donation (whole blood and\u002For platelet\u002Fplasma apheresis), meeting the following inclusion criteria:\n\n* Be in good health\n* Weigh at least 50 kg\n* Must be between 18 and 70 years of age for whole blood donation and between 18 and 65 years of age for plasma\u002Fplatelet donation by apheresis.\n\nExclusion Criteria:\n\nSubjects ineligible to donate blood",true,"65 Years",{"count":105,"type":21},30,[24],"\"Etablissement Français du Sang\" (EFS) prepares labile blood products from blood donations that are separated by type (red blood cells, plasma and platelets).\n\nThe \"Centre de Transfusion Sanguine des Armées\" (CTSA) produces an innovative labile blood product, LTO-WB, corresponding to group O leukocyte-free whole blood.\n\nThe objective of the PEDESTAL EFS study is to compare the inflammatory and biological characteristics of blood products prepared by the EFS vs. the labile blood product prepared by the CTSA.",[109,28,110,29,111],"Blood Donation","Blood Donors","Transfusion",[113,114,115,116,117,118,119,120,121,122],"blood","LTO-WB","characterization of labile blood products","whole blood","apheresis","plasma","platelet","red blood cells","inflammation","transfusion","2025-08-04",{"date":125,"type":37},"2025-08-06",{"date":127,"type":37},"2025-03-12",{"date":129,"type":21},"2028-02",{"name":131,"class":93},"Etablissement Français du Sang"]